Obsidian Therapeutics (NASDAQ:OBX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX) from a sell rating to a hold rating in a research report released on Sunday morning,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on OBX. Weiss Ratings began coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They issued a “sell (d-)” rating for the company. Leerink Partners began coverage on shares of Obsidian Therapeutics in a report on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 target price on the stock. William Blair upgraded shares of Obsidian Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Zacks Research upgraded shares of Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Finally, TD Cowen initiated coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Obsidian Therapeutics Stock Performance

Obsidian Therapeutics stock opened at $14.25 on Friday. Obsidian Therapeutics has a 1-year low of $11.52 and a 1-year high of $49.97. The company has a fifty day simple moving average of $15.62.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.